Clinical Trial Update: Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053) [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating immunogenicity and safety of V503 in Chinese males aged 9–19 for genital warts; status is active not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Genital Warts

Drugs mentioned

• V503

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Genital Warts | Phase 3 | Status: ACTIVE_NOT_RECRUITING